{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:12:32Z","timestamp":1756383152600,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[1999,5]]},"abstract":"<jats:p>\u25bcRaloxifene (Evista - Lilly) belongs to a family of drugs described as 'selective oestrogen receptor modulators' (abbreviated to 'SERMs' to reflect the American spelling of oestrogen) of which tamoxifen should probably be regarded as the first example. Raloxifene is licensed in the UK for the prevention of non-traumatic vertebral fractures in postmenopausal women considered at increased risk of osteoporosis. The drug is promoted as \"a new way of protecting women after the menopause without using hormones\". The manufacturer claims that raloxifene \"increases bone mass and reduces the risk of vertebral fracture\" and \"improves the lipid profile\", while causing \"placebo levels of breast symptoms...and uterine bleeding\". A further claim is that raloxifene \"has reduced the incidence of newly diagnosed breast cancer in clinical trials\". We examine these claims.<\/jats:p>","DOI":"10.1136\/dtb.1999.37533","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"33-36","source":"Crossref","is-referenced-by-count":6,"title":["\u25bcRaloxifene to prevent postmenopausal osteoporosis"],"prefix":"10.1136","volume":"37","member":"239","published-online":{"date-parts":[[1999,5,1]]},"reference":[{"key":"2025082623045499000_37.5.33.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01771666","article-title":"A pharmacological review of raloxifene","volume":"14","author":"Bryant","year":"1996","journal-title":"J Bone Miner Metab"},{"key":"2025082623045499000_37.5.33.2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01771666"},{"key":"2025082623045499000_37.5.33.3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1088"},{"key":"2025082623045499000_37.5.33.4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(98)05352-5","article-title":"The menopause","volume":"353","author":"Greendale","year":"1999","journal-title":"Lancet"},{"key":"2025082623045499000_37.5.33.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05352-5"},{"key":"2025082623045499000_37.5.33.6","unstructured":"Committee for Proprietary Medicinal Products (CPMP) . European Public Assessment Report. Evista London: European Medicines Evaluation Agency 1998."},{"key":"2025082623045499000_37.5.33.7","unstructured":"Raloxifene . Summary of product characteristics, UK. Eli Lilly and Company Limited August 1998."},{"key":"2025082623045499000_37.5.33.8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/bmj.318.7187.862","article-title":"Changing perceptions in osteoporosis","volume":"318","author":"Wilkin","year":"1999","journal-title":"BMJ"},{"key":"2025082623045499000_37.5.33.9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","article-title":"Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial","volume":"13","author":"Lufkin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2025082623045499000_37.5.33.10","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.11.1747"},{"key":"2025082623045499000_37.5.33.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.10.3425"},{"key":"2025082623045499000_37.5.33.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712043372301"},{"key":"2025082623045499000_37.5.33.13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/dtb.1996.34645","article-title":"Managing osteoporosis","volume":"34","year":"1996","journal-title":"DTB"},{"key":"2025082623045499000_37.5.33.14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bmj.317.7156.457","article-title":"Hormone replacement therapy","volume":"317","author":"Barrett-Connor","year":"1998","journal-title":"BMJ"},{"key":"2025082623045499000_37.5.33.15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-122-1-199501010-00002","article-title":"Estrogen replacement therapy and fractures in older women","volume":"122","author":"Cauley","year":"1995","journal-title":"Ann Intern Med"},{"key":"2025082623045499000_37.5.33.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-1-199501010-00002"},{"key":"2025082623045499000_37.5.33.17","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/S0002-9378(97)70091-7","article-title":"Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.","volume":"177","author":"Boss","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"2025082623045499000_37.5.33.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(97)70091-7"},{"key":"2025082623045499000_37.5.33.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.18.1445"},{"key":"2025082623045499000_37.5.33.20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"2025082623045499000_37.5.33.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.7.605"},{"key":"2025082623045499000_37.5.33.22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/oxfordjournals.aje.a009461","article-title":"Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in Southern Europe","volume":"147","author":"Varas-Lorenzo","year":"1998","journal-title":"Am J Epidemiol"},{"key":"2025082623045499000_37.5.33.23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(05)60331-5","article-title":"Raloxifene-associated hepatitis","volume":"352","author":"Vilches","year":"1998","journal-title":"Lancet"},{"key":"2025082623045499000_37.5.33.24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/09513599809015548","article-title":"The effects of tibolone","volume":"12","author":"Rymer","year":"1998","journal-title":"Gynecol Endocrinol"},{"key":"2025082623045499000_37.5.33.25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer","volume":"350","year":"1997","journal-title":"Lancet"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.1999.37533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:05:05Z","timestamp":1756274705000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.1999.37533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1999,5,1]]},"published-print":{"date-parts":[[1999,5]]}},"alternative-id":["10.1136\/dtb.1999.37533"],"URL":"https:\/\/doi.org\/10.1136\/dtb.1999.37533","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[1999,5]]}}}